Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study

Jung Hye Choi(Hanyang University Guri Hospital), In Soon Kim, Myung‐Ju Ahn(Sungkyunkwan University), Yeung‐Chul Mun(Ewha Womans University), Il Young Choi(Hanyang University), Chu Myung Seong, Young Yeul Lee(Hanyang University), Bong Seog Kim(Veterans Health Service Medical Center), Ho Suk Oh(Hanyang University), Heung Woo Lee, Seock Ah Im, Soon Nam Lee
Cancer Research and Treatment
June 30, 2003
10.4143/crt.2003.35.3.213
Cited by 0

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537